WO2024218655 - COMPOSITIONS AND METHODOLOGY FOR DELIVERY OF ALPHA-GALACTOSYLCERAMIDE COMPOUNDS
National phase entry:
Publication Number
WO/2024/218655
Publication Date
24.10.2024
International Application No.
PCT/IB2024/053714
International Filing Date
16.04.2024
Title **
[English]
COMPOSITIONS AND METHODOLOGY FOR DELIVERY OF ALPHA-GALACTOSYLCERAMIDE COMPOUNDS
[French]
COMPOSITIONS ET MÉTHODOLOGIE POUR L'ADMINISTRATION DE COMPOSÉS D'ALPHA-GALACTOSYLCÉRAMIDE
Applicants **
ENGENEIC MOLECULAR DELIVERY PTY LTD
Inventors
BRAHMBHATT, Himanshu
MACDIARMID, Jennifer
Priority Data
63/459,940
17.04.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
MOIP
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2303 | |
| EPO | Filing, Examination, Granting | 12053 | |
| Japan | Filing, Examination, Granting | 2208 | |
| South Korea | Filing, Examination, Granting | 1674 | |
| USA | Filing, Examination, Granting | 5940 |
Total:
24,178
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Compositions and methods are described for treating a disease, such as cancer or a viral or bacterial infection. More specifically, the provided compositions comprise encapsulated CD1d-restricted invariant Natural Killer T cell antigen, a bacterial α-galactosylceramide.[French]
L'invention concerne des compositions et des méthodes pour traiter une maladie, comme un cancer ou une infection virale ou bactérienne. Plus spécifiquement, les compositions de l'invention contiennent un antigène de lymphocyte T tueur naturel invariant CD1d restreint encapsulé, un α-galactosylcéramide bactérien.